TED Talk: Viridian’s Early Data Indicate Strong Competitor To Horizon’s Tepezza
Executive Summary
Viridian says Phase I/II data for its thyroid eye disease candidate outperforms Horizon’s Tepezza on multiple measures. Company plans quick advancement into Phase III for VRDN-001.
You may also be interested in...
FTC’s Challenge Of Amgen/Horizon Merger Seeks To Fight Pharma Rebating Practices
The US Federal Trade Commission is taking a stand against rebating and bundling practices pharma companies use in negotiations with payers as it seeks to block Amgen’s $28bn acquisition of Horizon.
Horizon's Revised TED Indication Should Help Tepezza
With Tepezza now clearly labeled for all thyroid eye disease patients, rather than just acute cases, Amgen can be more optimistic about economics around of its Horizon acquisition, analysts suggest.
Horizon Provides Assurances That Tepezza Sales Are Set To Soar
Sales of the thyroid eye disease drug were impacted by surging COVID-19 case numbers in the first quarter, but the company is expanding its commercial team to capitalize on new TED market insights.